vida: extract claims from 2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution

- Source: inbox/queue/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/bmi-fails-as-malnutrition-indicator-in-obese-hfpef-enabling-sarcopenic-obesity-paradox.md

@@ -0,0 +1,16 @@
+---
+type: claim
+domain: health
+description: The obesity paradox in HFpEF creates a measurement failure where standard eligibility criteria (BMI ≥30) cannot distinguish between patients who will benefit from weight loss and those at risk from muscle loss
+confidence: experimental
+source: Journal of Cardiac Failure 2024, HFpEF malnutrition prevalence data
+created: 2026-04-11
+title: BMI fails as a malnutrition indicator in obese HFpEF patients because sarcopenic obesity allows high body fat and low muscle mass to coexist at BMI 30-plus
+agent: vida
+scope: structural
+sourcer: Journal of Cardiac Failure / PMC
+---
+
+# BMI fails as a malnutrition indicator in obese HFpEF patients because sarcopenic obesity allows high body fat and low muscle mass to coexist at BMI 30-plus
+
+Among hospitalized HFpEF patients, 32.8% are obese, yet malnutrition is present even in patients with average BMI 33 kg/m². This occurs through sarcopenic obesity—the co-occurrence of low skeletal muscle mass with increased body fat. BMI measures total body mass relative to height but cannot distinguish between fat mass and lean mass. In HFpEF, this creates a clinical blind spot: patients who meet obesity criteria (BMI ≥30) and appear eligible for weight-loss interventions may simultaneously harbor muscle insufficiency that weight loss will worsen. The measurement failure has therapeutic implications: GLP-1 eligibility criteria use BMI ≥30, but this threshold cannot identify which obese patients have adequate muscle reserves versus which have sarcopenic obesity where further muscle loss (20-50% of GLP-1-induced weight loss) will accelerate the malnutrition that independently doubles adverse event risk. The paradox is structural: the same BMI value can represent two opposite clinical states—robust obesity where weight loss is beneficial versus sarcopenic obesity where weight loss is harmful—requiring body composition assessment beyond BMI for individualized risk stratification.

domains/health/glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The therapeutic window is narrow because the patients most eligible for GLP-1 (obese HFpEF) often harbor hidden sarcopenic obesity that GLP-1's appetite suppression worsens
+confidence: experimental
+source: Journal of Cardiac Failure 2024, STEP-HFpEF trial data
+created: 2026-04-11
+title: GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk
+agent: vida
+scope: causal
+sourcer: Journal of Cardiac Failure / PMC
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk
+
+GLP-1 receptor agonists reduce HF hospitalization and mortality by 40%+ in obese HFpEF patients (STEP-HFpEF). However, this same population faces a hidden paradox: 32.8% of hospitalized HFpEF patients are obese, and among these obese patients (average BMI 33 kg/m²), many are malnourished with sarcopenic obesity—low skeletal muscle mass coexisting with increased body fat. BMI poorly reflects nutritional status in this population. GLP-1 therapy creates competing mechanisms: (1) Semaglutide reduces total energy intake by 24% compared to placebo, compromising macro- and micronutrient intake in already vulnerable patients. (2) GLP-1-induced weight loss includes 20-50% from fat-free mass (lean mass including skeletal muscle). (3) Malnutrition in HFpEF carries nearly 2-fold increased risk of adverse events including all-cause mortality and hospitalization, independent of cardiac disease. (4) Skeletal muscle tissue loss carries prognostic significance independent of total weight reduction in HF. The result is a clinical tension requiring individualized risk stratification: the cardiac benefit mechanism (reduced volume overload, improved metabolic profile) competes with the nutritional harm mechanism (accelerated sarcopenia in patients where muscle loss already doubles mortality risk). This is not a simple risk-benefit calculation but a structural paradox where the same intervention helps one organ system while potentially harming another critical determinant of outcomes.